Login to Your Account


EpiTherapeutics, Abbott in Epigenetics Oncology Deal

By Cormac Sheridan


Wednesday, December 22, 2010
EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International)

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.